Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may ...

A once weekly injection of semaglutide, the main ingredient in Ozempic and Wegovy, may help problem drinkers kick their cravings. In a new study, the drug, known for treating type 2 diabetes and ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

The Real Housewives of New Jersey star spoke exclusively to HELLO! about her menopause struggles, life on Ozempic and refreshing relationship goals ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.